Risk of malignant neoplasms after liver transplantation: A population-based study

Liver Transplantation

Volumn 14, Issue 10, 2008, Pages 1428-1436

  Åberg, Fredrik ^a,c   Pukkala, Eero ^b   Höckerstedt, Krister ^a   Sankila, Risto ^b   Isoniemi, Helena ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c Surgical Hospital   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FINLAND; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO;

ADOLESCENT; ADULT; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; YOUNG ADULT;

EID: 57849169437     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21475     Document Type: Article

References (61)

1. Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25: 1383-1384.
2. Starzl TE. Five years experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416.
3. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106-112.
4. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969;8:209-212.
5. Penn I. Neoplastic complications of transplantation. Semin Respir Infect 1993;8:233-239.
6. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89: 1221-1227.
7. Brunner FP, Landais P, Selwood NH, for the European Dialysis and Transplantation Association-European Renal Association. Malignancies after renal transplantation: the EDTA-ERA registry experience. Nephrol Dial Transplant 1995;10(suppl 1):74-80.
8. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF Jr. Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol 1987;126:370-376.
9. Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney transplanted population. Transpl Int 2000; 13(suppl 1):S394-S398.
10. Pond F, Serpell JW, Webster A. Thyroid cancer in the renal transplant population: epidemiological study. ANZ J Surg 2005;75:106-109.
11. Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997;71:517-520.
12. Chapman J, Webster AC. Cancer Report: ANZDATA Registry 2004 Report. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry; 2004.
13. Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973;2:55-57.
14. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-1466.
15. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886-1887.
16. Blohme I, Brynger H. Malignant disease in renal transplant patients. Transplantation 1985;39:23-25.
17. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498-504.
18. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schulger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781-789.
19. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-1150.
20. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44:1172-1181.
21. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
22. Kelly DM, Sukru E, Stephen RG, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998;83:1237-1243.
23. Berenguer M, Prieto M, Bustamante M, Carrasco D, López-Andújar R, Mir J, Berenguer J. Incidence of de novo neoplasms after liver transplantation. Med Clin 1998;111: 481-484.
24. Peyrègne V, Ducerf C, Adham M, de la Roche E, Berthoux N, Bancel B, et al. De novo cancer after orthotopic liver transplantation. Transpl Proc 1998;30:1484-1485.
25. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: a single center study. Transpl Proc 1993;25: 1397-1399.
26. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66:1193-1200.
27. Rubio E, Moreno JM, Turrión VS, Jiménez M, Lucena JL, Cuervas-Mons V. De novo malignancies and liver transplantation. Transpl Proc 2003;35:1896-1897.
28. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002;8: 482-487.
29. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002;8:285-291.
30. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001; 7:971-975.
31. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transpl 2004;4:596-604.
32. Briceno J, López-Cillero P, Fraga E, Pera C. Results of liver transplantation in a Spanish group: a report from the Cordoba unit. In: Cecka JM, Terasaki PI, eds. Clinical Transplant 2001. Los Angeles, CA: UCLA Immunogenetics Center, 2001:187-194.
33. Jaurrieta E, Casais L, Figueras J, Ramos E, Lama C, Rafecas A, et al. Analysis of 500 liver transplantations at Bellvitge Hospital. Med Clin 2000;115:521-529.
34. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001;72:619-626.
35. Jiménez C, Rodríguez D, Marqués E, Loinaz C, Alonso O, Hernández-Vallejo G, et al. De novo tumors after orthotopic liver transplantation. Transpl Proc 2002;34:297-298.
36. Bessa X, Andreu H, Cirera I, Rimola A, Navasa M, Grande L, et al. De novo tumors in adult patients with hepatic transplant. Gastroenterol Hepatol 1997;20: 442-445.
37. Valero JM, Rubio E, Moreno JM, Pons F, Sánchez-Turrión V, Cuevas-Mons V. De novo malignancies in liver transplantation. Transpl Proc 2003;35:709-711.
38. Catalina MV, de Diego A, García-Sánchez A, Escudero M, Salcedo M, Bañares R, Clemente G. Characterization of de novo malignancies in liver transplantation. Gastroenterol Hepatol 2003; 26:57-63.
39. Schmilovitz-Weiss H, Mor E, Sulkes J, Bar-Nathan N, Shaharabani E, Melzer E, et al. De novo tumors after liver transplantation: a single-center experience. Transpl Proc 2003;35:665-666.
40. Safadi R, Ilan Y, Eid A, Galun E, Ashur Y, Goldin E, et al. Solid tumors after liver transplantation. Transpl Proc 1999;31:1894-1895.
41. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005;27:80:759-764.
42. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001; 7:S109-S118.
43. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540.
44. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
45. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
46. Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol 2006;44:13-18.
47. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-369.
48. Pukkala E. Use of record linkage in small-area studies. In: Elliot P, Guzick J, English D, Stern R, eds. Geographical and Environmental Epidemiology. Oxford, England: Oxford University Press; 1992:125-131.
49. Aberg F, Koivusalo AM, Hockerstedt K, Isoniemi H. Renal dysfunction in liver transplant patients: comparing patients transplanted for liver tumor or acute or chronic disease. Transpl Int 2007;20:591-599.
50. Matinlauri IH, Nurminen MM, Hockerstedt KA, Isoniemi HM. Changes in liver graft rejections over time. Transplant Proc 2006;38:2663-2666.
51. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005;11:89-97.
52. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hézode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74:1103-1109.
53. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000;6:570-574.
54. Hézode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999;30:775-778.
55. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996;2:52-59.
56. Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005;56:87-99.
57. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002;6:396-399.
58. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res 1976;36:2923-2927.
59. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76:1289-1293.
60. Triemer HL, Pearson TC, Odom KL, Larsen CP. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation. Clin Transplant 2000;14(pt 2):413-420.
61. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003;76:984-988.